BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 11241310)

  • 1. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma.
    Yoshizaki T; Maruyama Y; Sato H; Furukawa M
    Int J Cancer; 2001 Jan; 95(1):44-50. PubMed ID: 11241310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis.
    Katayama A; Bandoh N; Kishibe K; Takahara M; Ogino T; Nonaka S; Harabuchi Y
    Clin Cancer Res; 2004 Jan; 10(2):634-40. PubMed ID: 14760086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation between MMP-2 activation and MT1-MMP mRNA expression in thymic epithelial tumors].
    Wang Y; Ueda Y; Shimasaki M; Liu N; Wang EH
    Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):18-23. PubMed ID: 16608644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
    Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
    Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization.
    Davidson B; Goldberg I; Kopolovic J; Lerner-Geva L; Gotlieb WH; Ben-Baruch G; Reich R
    Gynecol Oncol; 1999 Jun; 73(3):372-82. PubMed ID: 10366463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
    Schwandner O; Schlamp A; Broll R; Bruch HP
    Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with N-nitrosobis(2-oxopropyl)amine.
    Iki K; Tsutsumi M; Kido A; Sakitani H; Takahama M; Yoshimoto M; Motoyama M; Tatsumi K; Tsunoda T; Konishi Y
    Carcinogenesis; 1999 Jul; 20(7):1323-9. PubMed ID: 10383907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP.
    Bernardo MM; Fridman R
    Biochem J; 2003 Sep; 374(Pt 3):739-45. PubMed ID: 12755684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2.
    Kayano K; Shimada T; Shinomiya T; Nakai S; Hisa Y; Aoki T; Seiki M; Okada Y
    J Pathol; 2004 Apr; 202(4):403-11. PubMed ID: 15095267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane type I-matrix metalloproteinase-mediated degradation of type I collagen by oral squamous cell carcinoma cells.
    Aznavoorian S; Moore BA; Alexander-Lister LD; Hallit SL; Windsor LJ; Engler JA
    Cancer Res; 2001 Aug; 61(16):6264-75. PubMed ID: 11507081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma.
    Sakamoto A; Oda Y; Iwamoto Y; Tsuneyoshi M
    J Cancer Res Clin Oncol; 1999 Oct; 125(10):541-8. PubMed ID: 10473866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
    Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
    Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.
    Jo Y; Yeon J; Kim HJ; Lee ST
    Biochem J; 2000 Feb; 345 Pt 3(Pt 3):511-9. PubMed ID: 10642509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma.
    Sier CF; Zuidwijk K; Zijlmans HJ; Hanemaaijer R; Mulder-Stapel AA; Prins FA; Dreef EJ; Kenter GG; Fleuren GJ; Gorter A
    Int J Cancer; 2006 Jun; 118(12):2991-8. PubMed ID: 16425263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis.
    Sutinen M; Kainulainen T; Hurskainen T; Vesterlund E; Alexander JP; Overall CM; Sorsa T; Salo T
    Br J Cancer; 1998 Jun; 77(12):2239-45. PubMed ID: 9649139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: implications for lymph node metastasis.
    Shimada T; Nakamura H; Yamashita K; Kawata R; Murakami Y; Fujimoto N; Sato H; Seiki M; Okada Y
    Clin Exp Metastasis; 2000; 18(2):179-88. PubMed ID: 11235994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the regulation of matrix metalloproteinase 2 activation: from basic research to clinical implication (Review).
    Yoshizaki T; Sato H; Furukawa M
    Oncol Rep; 2002; 9(3):607-11. PubMed ID: 11956636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2.
    Toth M; Bernardo MM; Gervasi DC; Soloway PD; Wang Z; Bigg HF; Overall CM; DeClerck YA; Tschesche H; Cher ML; Brown S; Mobashery S; Fridman R
    J Biol Chem; 2000 Dec; 275(52):41415-23. PubMed ID: 10998420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.